Relmada Therapeutics (RLMD) Research & Development (2014 - 2026)
Relmada Therapeutics' Research & Development was $8.39 million in Q2 2026, up 197.7% from $2.82 million a year earlier and up 3.8% from the prior quarter.
Powered by 
Analysis
Relmada Therapeutics (RLMD) Research & Development (2014 - 2026) Analysis & Trends
On a trailing twelve-month basis, Relmada Therapeutics' Research & Development was $28.59 million through Jun 30, 2026, down 22.6% year-over-year; for FY2025, it was $26.88 million, down 41.8% from FY2024.
- Research & Development has now declined for three consecutive years, with a five-year compound annual growth rate of -5.7% (FY2020 to FY2025).
- In earlier years, Research & Development was $46.18 million in FY2024 (-15.7%), $54.81 million in FY2023 (-51.6%), $113.32 million in FY2022 (+25.1%) and $90.62 million in FY2021 (+151.9%).
- The Q2 2026 figure marks the highest quarterly Research & Development since Q1 2025.
- Compared with a year earlier, Research & Development was higher in two of the last eight quarters, with an average decline of 3.5%.
- The best year-over-year quarter for Research & Development over five years was Q3 2021 (growth of 202.5%); the worst was Q2 2025 (a decline of 73.7%).
- Per Business Quant data, RLMD's Research & Development in the three quarters before Q2 2026 was $8.09 million (Q1 2026), $8.07 million (Q4 2025) and $4.04 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,136.97 Bn | 1,105.55 Bn | 19.71 Bn | 3.82 Bn |
| 2 | Johnson & Johnson | 619.72 Bn | 538.25 Bn | 17.26 Bn | 3.65 Bn |
| 3 | AbbVie | 503.40 Bn | 476.52 Bn | 12.70 Bn | 2.34 Bn |
| 4 | Merck | 370.15 Bn | 324.53 Bn | 12.21 Bn | 9.74 Bn |
| 5 | Novartis Ag | 298.64 Bn | 262.63 Bn | 11.24 Bn | 2.85 Bn |
| 6 | Astrazeneca | 261.07 Bn | 234.76 Bn | 12.86 Bn | 4.05 Bn |
| 7 | Amgen | 237.00 Bn | 192.40 Bn | 7.24 Bn | 1.87 Bn |
| 8 | Gilead Sciences | 191.24 Bn | 165.43 Bn | 6.22 Bn | 1.76 Bn |
| 9 | Pfizer | 170.31 Bn | 116.96 Bn | 10.94 Bn | 2.81 Bn |
| 10 | Relmada Therapeutics | 361.29 Mn | -197.30 Mn | - | 8.39 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 8.39 Mn |
| Mar 31, 2026 | 8.09 Mn |
| Dec 31, 2025 | 8.07 Mn |
| Sep 30, 2025 | 4.04 Mn |
| Jun 30, 2025 | 2.82 Mn |
| Mar 31, 2025 | 11.95 Mn |
| Dec 31, 2024 | 11.00 Mn |
| Sep 30, 2024 | 11.15 Mn |
| Jun 30, 2024 | 10.72 Mn |
| Mar 31, 2024 | 13.31 Mn |
| Dec 31, 2023 | 14.75 Mn |
| Sep 30, 2023 | 10.45 Mn |
| Jun 30, 2023 | 13.74 Mn |
| Mar 31, 2023 | 15.86 Mn |
| Dec 31, 2022 | 26.87 Mn |
| Sep 30, 2022 | 30.53 Mn |
| Jun 30, 2022 | 30.91 Mn |
| Mar 31, 2022 | 25.01 Mn |
| Dec 31, 2021 | 25.27 Mn |
| Sep 30, 2021 | 33.99 Mn |
API Access
Relmada Therapeutics Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=RLMD&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "RLMD", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=RLMD&period=max&api_key=YOUR_API_KEY");
const data = await res.json();